CUPERTINO, Calif., April 24, 2018 /PRNewswire/ -- In
conjunction with DURECT Corporation's(Nasdaq: DRRX) first quarter
2018 financial results press release, you are invited to listen to
a conference call that will be broadcast live over the internet on
Wednesday, May 2, 2018 at
4:30 pm Eastern Time (1:30 pm Pacific Time).
A live audio webcast of the presentation will be available by
accessing DURECT's homepage at www.durect.com and clicking
"Investor Relations." If you are unable to participate during
the live webcast, the call will be archived on DURECT's website
under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing new
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR-928, a new chemical
entity in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury, hepatic and renal diseases such as
nonalcoholic steatohepatitis (NASH) and PSC, and inflammatory skin
conditions such as psoriasis and atopic dermatitis. DURECT's
advanced oral and injectable delivery technologies are designed to
enable new indications and enhanced attributes for small-molecule
and biologic drugs. One late-stage product candidate in this
category is POSIMIR® (SABER®-Bupivacaine), an
investigational locally-acting, non-opioid analgesic intended to
provide up to 3 days of continuous pain relief after surgery.
Another late stage product candidate is REMOXY® ER
(oxycodone), an investigational pain control drug based on DURECT's
ORADUR® technology, for which the FDA has set a PDUFA
target action date of August 7,
2018. In addition, for the assignment of certain patent
rights, DURECT may receive a milestone payment upon NDA approval
and single digit sales-based earn-out payments from U.S. net sales
of Indivior's RBP-7000 investigational drug for schizophrenia, for
which Indivior has submitted an NDA and for which the FDA has set a
PDUFA target action date of July 28,
2018. For more information, please visit www.durect.com.
NOTE: POSIMIR®, SABER®, and
ORADUR® are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners.
DUR-928, RBP-7000, REMOXY ER and POSIMIR are drug candidates under
development and have not been approved for commercialization by the
U.S. Food and Drug Administration or other health authorities.
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-invites-you-to-join-its-first-quarter-2018-earnings-conference-call-300635582.html
SOURCE DURECT Corporation